Evolution of the burden of active hepatitis C virus infection in England from September 2015 to September 2016: a repeated cross-sectional analysis.

ABSTRACT:

Objective

To evaluate the impact of treatment with new direct-acting antivirals (DAAs) on the prevalent hepatitis C virus (HCV) population in England.

Design

A repeated cross-sectional analysis.

Setting

Four secondary care hospitals in England.

Participants

Patients who, in 2015 and/or 2016, had chronic HCV infection and were alive were eligible, regardless of the type of HCV intervention received.

Outcome measures

Data including intravenous drug use (IVDU) status, HCV genotype, cirrhosis status, HCV treatment history, vital status and treatment outcomes were collected at two time points in 2015 and 2016 using electronic case report forms.

Results

There were 1605 and 1355 patients with active chronic HCV in 2015 and 2016, respectively. Between 201

SUBMITTER: Lacoin L 

PROVIDER: S-EPMC6687009 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature